FOLH1 and prostate cancer: Results demonstrated the potential of using imaging biomarkers from PSMA-PET/CT images for prognosis prediction before the treatment, which provides clinicians valuable information for customizing the treatment paradigm to improve the outcomes for primary prostate cancer patients.